中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.015 seconds)

    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
    2.
    发明申请
    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN 审中-公开

    公开(公告)号：US20170119868A1

    公开(公告)日：2017-05-04

    申请号：US15393092

    申请日：2016-12-28

    Applicant: GlaxoSmithKline Biologicals SA

    Inventor： Mario CONTORNI ,  Lorenzo TARLI

    IPC: A61K39/095

    CPC classification number: A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

    IMMUNOGENIC COMPOSITIONS
    3.
    发明申请
    IMMUNOGENIC COMPOSITIONS 有权

    公开(公告)号：US20250049906A1

    公开(公告)日：2025-02-13

    申请号：US18894961

    申请日：2024-09-24

    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

    Inventor： Mario CONTORNI ,  Mariagrazia PIZZA ,  Anja SEUBERT

    IPC: A61K39/00 ,  A61P31/04

    Abstract: The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
    4.
    发明申请
    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN 审中-公开

    公开(公告)号：US20170360915A1

    公开(公告)日：2017-12-21

    申请号：US15604054

    申请日：2017-05-24

    Applicant: GlaxoSmithKline Biologicals SA

    Inventor： Mario CONTORNI ,  Lorenzo TARLI

    IPC: A61K39/095 ,  A61K39/00

    CPC classification number: A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

    MENINGOCOCCAL VACCINE FORMULATIONS
    5.
    发明申请
    MENINGOCOCCAL VACCINE FORMULATIONS 审中-公开
    MENINGOCOCCAL VACCINE配方

    公开(公告)号：US20160228529A1

    公开(公告)日：2016-08-11

    申请号：US15011216

    申请日：2016-01-29

    Applicant: GlaxoSmithKline Biologicals SA

    Inventor： Mario CONTORNI ,  Jina KAZZAZ ,  Derek O'HAGAN ,  Manmohan SINGH ,  Mildred UGOZZOLI

    IPC: A61K39/095

    CPC classification number: A61K39/095 ,  A61K9/107 ,  A61K9/19 ,  A61K2039/55566

    Abstract: A dual formulation for vaccines against Neisseria meningitidis serogroup B (‘Men-B’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a Men-B immunogenic component in lyophilised form. The lyophilised Men-B antigens can be reconstituted into liquid adjuvanted form at the time of use ready for administration to a patient. This formulation has been found to give excellent result in terms of both stability and immunogenicity. The lyophilised component can also include one or more conjugated saccharides from N. meningitidis in serogroups A, C, W135 and/or Y.

    Abstract translation: 针对脑膜炎奈瑟氏球菌血清群B（'Men-B'）的疫苗的双重配方包括（i）水包油乳剂佐剂和（ii）冻干形式的Men-B免疫原性组分。 冻干的Men-B抗原可以在使用时重建成液体佐剂形式，准备用于给予患者。 已经发现这种配方在稳定性和免疫原性方面都获得了优异的结果。 冻干组分还可以包含一种或多种血清群A，C，W135和/或Y中脑膜炎奈瑟氏球菌的共轭糖。

    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
    8.
    发明申请
    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN 审中-公开

    公开(公告)号：US20190151430A1

    公开(公告)日：2019-05-23

    申请号：US16269370

    申请日：2019-02-06

    Applicant: GlaxoSmithKline Biologicals SA

    Inventor： Mario CONTORNI ,  Lorenzo TARLI

    IPC: A61K39/095 ,  A61K47/02

    CPC classification number: A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    Abstract: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

Patent Agency Ranking